Axsome Therapeutics Earnings Preview: Key Financial Insights

The anticipated EPS of -$0.70 and revenue of $193.3 million for the quarter ending December 2025.Negative P/E ratio of -40.57 but potential growth indicated by revenue projections.Concerns over negative operating cash flow with an enterprise value to operating cash flow ratio of -91.91.Axsome Therapeutics, listed on NASDAQ:AXSM, is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company is set to release its quarterly earnings on February 23, 2026. Wall ...